Import Licence from the Ministry of Commerce for Medical Devices in Myanmar

1. Key takeaways

Obtaining a medical device registration certificate from the Myanmar FDA does not in itself confer the right to import. In addition to the registration certificate, the importer must apply to the Ministry of Commerce for an Import Licence for each individual shipment of goods. This is an independent step running in parallel with FDA registration, and it falls under the jurisdiction of the commerce authorities rather than the health authorities. A company that plans its shipments around the registration timeline alone will discover that a second, separate approval governs whether the goods can physically enter the country.

GRZAN insight: according to industry observation in 2026, the processing time for the Ministry of Commerce import licence has lengthened owing to import control policies (aimed at preserving foreign exchange reserves). Companies must treat this step as an independent time item when arranging shipping plans; it cannot be merged into the FDA registration cycle when estimating schedules. The procedural coordinates can be remembered as: 2 parallel procedures, 1 per-shipment application action, and 1 pre-shipment verification.

• 2 parallel procedures — FDA registration governs whether the product is admitted to the market; the Ministry of Commerce import licence governs whether a given shipment can enter the country.
• 1 per-shipment application — the import licence is applied for shipment by shipment, so it is a recurring operational action rather than a one-off project step.
• 1 pre-shipment verification — before dispatch, confirm that the registration certificate number, batch numbers, and labels are consistent with the approved items.

2. Legal basis

The table below sets out the regulatory elements of the import licence regime. It distinguishes the two authorities and their respective mandates, records the sequence between the import recommendation letter and the import licence itself, captures the 2026 observation on processing times, and lists the document checks and record-keeping duties that accompany customs clearance and post-market oversight.

3. Expert insights

Insight 1: the two procedures cannot substitute for each other. The FDA registration certificate answers whether the product is admitted to the market; the Ministry of Commerce import licence answers whether this specific shipment of goods can enter the country. Missing either one makes delivery impossible. Because the two authorities belong to different systems — health and commerce — neither approval carries any implication for the other, and each must be pursued on its own track with its own documentation.

Insight 2: the import licence is applied for shipment by shipment, making it a recurring action. Unlike the registration certificate, which is valid for five years, the import licence belongs to the category of routine matters that must be handled for every dispatch, so it belongs in the operational process rather than the project process. A team that assigns the licence only to project staff will find that day-to-day shipments run ahead of the paperwork; the application step needs owners and timing inside the standard shipping workflow.

Insight 2 supplement: there is a sequence between the import recommendation letter and the import licence. The recommendation letter comes first, and only after it has been obtained may the application for the import licence be made. Treating the two as a single package, or starting the licence application before the letter is in hand, misorders the steps and costs time that a correct sequence would have saved.

Insight 3: the lengthened processing times observed in 2026 are a practical observation. The specific processing duration must be confirmed with the competent authority or a local agent, and schedules should not be built on historical experience. Because the extension is tied to import control policies rather than to the product itself, it can vary with policy conditions, which is precisely why the current duration — not last year’s — should drive the shipping plan.

Insight 4: document consistency is tested in concentrated form at customs clearance. The registration certificate number, the batch numbers, and the labels must all align, and any deviation among the three can cause the goods to be held. The check is mechanical and unforgiving: a single mismatched field is enough to trigger detention, so the alignment should be verified before the goods leave rather than discovered when they arrive.

Insight 5: import records are the evidential basis for post-market compliance. The authorised representative must keep complete records in order to respond to audits or adverse event investigations. When an investigation asks which batches entered the market, when, and under which approvals, the import record is the document that answers it; gaps in that record become gaps in the compliance position.

4. Practical recommendations

• Schedule the import licence as an independent step. Do not merge its timing into the FDA registration cycle when estimating schedules.
• Establish an operational process for per-shipment applications. Assign a responsible person and defined time points for each application.
• Reserve time on the basis of the lengthened 2026 processing times. Confirm the current processing duration with a local agent before committing to shipping dates.
• Complete a consistency check of the three fields before shipment. Verify the registration certificate number, the batch numbers, and the labels against the approved items.
• Require the authorised representative to keep complete import records. Review the completeness of the records on a periodic basis.

5. Verification checklist

• □ Confirmed that the import licence is a step independent of FDA registration
• □ Confirmed that the import licence must be applied for shipment by shipment
• □ Established an operational process for per-shipment applications
• □ Reserved processing time on the basis of the current practical estimate
• □ Completed the consistency check of registration certificate number, batch numbers, and labels
• □ Required the authorised representative to keep complete import records
• □ Incorporated the registration ledger into management

Regulatory information verified as of 29 October 2026.

In the Southeast Asian market, GRZAN’s core strengths concentrate on three points. First, distinguishing the legislative progress of each ASEAN member state’s dedicated medical device law — Singapore, Malaysia, Thailand, Indonesia, the Philippines, Vietnam and others have each established their own written medical device regulatory framework, whereas Myanmar has not yet enacted a dedicated law; its rules are assembled from three layers: the technical framework of the ASEAN Medical Device Directive, administrative guidance from the competent authority, and the catch-all authorisation of the Public Health Law 1972, so compliance certainty is markedly lower than in markets where dedicated legislation is complete. Second, local authorised representative services, in which GRZAN can act as the statutory representative of the manufacturer in these countries, carrying registration submissions, regulatory communications, and post-market reporting obligations. Third, quality system and laboratory testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com